This trial is active, not recruiting.

Condition malaria
Treatment amodiaquine-artesunate versus amodiaquine
Phase phase 4
Sponsor Charite University, Berlin, Germany
Collaborator University for Development Studies, Tamale, Ghana
Start date October 2005
End date December 2005
Trial size 400 participants
Trial identifier NCT00238017, A50068, NP05-M4


The purpose of this study is to compare the efficacy and safety of two antimalarial drug regimes, namely amodiaquine versus amodiaquine-artesunate, in the treatment of children with uncomplicated malaria. Also, genetic host factors which might influence efficacy and/or safety will be examined.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

Parasitological and clinical cure rates by days 14 and 28
time frame:
Parasite and fever clearance times
time frame:
Carrier rates of sexual parasite stages at days 7, 14 and 28
time frame:
Incidence rates of adverse events
time frame:

Secondary Outcomes

Incidence rate of haematological and biochemical evidence of drug-induced toxicity
time frame:
Primary endpoints in children with and without various genetic host factors
time frame:

Eligibility Criteria

Male or female participants from 6 months up to 59 months old.

Inclusion Criteria: - Male and female outpatients aged 6 to 59 months - Body weight >5 kg - Uncomplicated Plasmodium falciparum malaria - Mono-infection with P. falciparum with an asexual parasite density between 2,000 to 200,000 parasites/μl - Axillary temperature ≥37.5°C - Ability to tolerate oral therapy - Informed consent by the legal representative of the subject - Residence in study area Exclusion Criteria: - Previous participation in this clinical trial - Haemoglobin <5 mg/dl - Mixed plasmodial infection - Danger signs (unable to drink; repeated vomiting; recent history of convulsions;lethargic or unconscious state; unable to stand up or to sit) and signs of severe malaria as defined by WHO. - Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection) - Concomitant disease masking assessment of response - History of allergy or intolerance against study medications

Additional Information

Official title A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria
Principal investigator Rowland N Otchwemah, PhD
Description Malaria remains a major cause of morbidity and mortality among children in sub-Saharan Africa. Current malaria control largely consists of rapid treatment of patients. Amodiaquine-artesunate and other combinatory treatment regimes including amodiaquine are now being introduced as first-line antimalarial drugs in several African countries. However, data on the efficacy and safety of amodiaquine and amodiaquine-artesunate are scarce. In addition, there is evidence that common genetic host factors, e.g. sickle cell trait, may influence efficacy and safety of these drugs. To examine efficacy and safety of the named drugs as well as a potential influence of genetic host factors on these outcomes a randomized, double blind trial among 400 children with uncomplicated malaria is performed in northern Ghana.
Trial information was received from ClinicalTrials.gov and was last updated in February 2006.
Information provided to ClinicalTrials.gov by Charite University, Berlin, Germany.